Zimmer Biomet Holdings, Inc. (ZBH): Daniel E. Williamson , Group President of Zimmer Biomet Holdings, Inc. sold 10,000 shares on Jun 9, 2016. The Insider selling transaction was reported by the company on Jun 10, 2016 to the Securities and Exchange Commission. The shares were sold at $119.77 per share for a total value of $1,194,932.62 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 10, 2016, Stuart G. Kleopfer (President, Americas) sold 11,000 shares at $119.68 per share price.On Apr 18, 2016, Daniel P Florin (Sr. VP, CFO) sold 10,000 shares at $114.98 per share price.Also, On Mar 22, 2016, David C Dvorak (President and CEO) sold 1,540 shares at $104.16 per share price.On Dec 3, 2015, David A. Jr. Nolan (Group President) sold 3,435 shares at $102.62 per share price.
Shares of Zimmer Biomet Holdings Inc (ZBH) ended Thursday, Jun 9, 2016 session in red amid volatile trading. The shares closed down -0.36 points or -0.30% at $119.4 with 11,15,027 shares getting traded. Post opening the session at $119.3, the shares hit an intraday low of $118.81 and an intraday high of $120.13 and the price vacillated in this range throughout the day. The company has a market cap of $23,789 M and the number of outstanding shares has been calculated to be 19,92,38,890 shares. The 52-week high of Zimmer Biomet Holdings Inc is $123.43 and the 52-week low is $88.27.
On May 23, 2016, Zimmer Biomet Holdings Inc announced a cash dividend of $0.2400. The company’s management has announced Jun 22, 2016 as the ex-dividend date and fixed the record date on Jun 24, 2016. The payable date has been fixed on Jul 29, 2016.
Company has been under the radar of several Street Analysts.Zimmer Biomet Holdings Inc is Initiated by Guggenheim to Neutral. The Rating was issued on Jun 9, 2016.Zimmer Biomet Holdings Inc is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 135 from a previous price target of $130 .The Rating was issued on Apr 29, 2016.Zimmer Biomet Holdings Inc is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 132 from a previous price target of $120 .The Rating was issued on Apr 15, 2016.Zimmer Biomet Holdings Inc is Initiated by Nomura to Buy. The Rating was issued on Mar 17, 2016.
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.